Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1209 vs pertuzumab plus trastuzumab and docetaxel in HER2-positive, hormone receptor–negative early/locally advanced breast cancer
CTR20201073Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1209 in breast cancer, sponsored by Qilu Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
QL1209
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20201073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201073.